LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.…
Medical costs are crushing insurers—and lifting LivaNova stock
LivaNova (NASDAQ: LIVN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 3,300 employees.
The shares were at 90.73 USD on 20 November 2026, up 60.2% over 52 weeks. Its 52-week range is 52.37 USD to 99.38 USD: the price is 8.7% below the high and 73.2% above the low.
At a market capitalisation of 5.00B USD, it trades at 26.0 times trailing earnings and 19.2 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, so LIVN is valued in line with them.
LivaNova reports return on equity of -20.2%, an operating margin of 14.3% and revenue up 9.9% year over year.
It holds more cash than debt, a net cash position of 206.40M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 105.09 USD is 15.8% above the current price. The next earnings report is expected on 24 February 2027.